News

If approved, Imfinzi could be administered intravenously every four weeks at a fixed dose of 1500mg in unresectable Stage III NSCLC after chemoradiation therapy and previously treated advanced bladder cancer,

TYVYT, which was co-developed by Innovent and Lilly in China, is an anti-PD-1 monoclonal antibody immuno-oncology medicine. The duo began selling the drug in the country since 2019

Situated in Frederick of Colorado, the advanced facility is engaged in the development and manufacturing of oligos that are short DNA and RNA molecules used for the creation

The trial was a randomized, double-blind, placebo-controlled, multi-center, dose escalation study assessing the safety and efficacy of F351 for Hepatic Fibrosis in Chronic Viral Hepatitis B patients in

In a series of experiments conducted by Dr. Stephen Barr, Associate Professor in the Department of Microbiology and Immunology at Western University, both BOLD-100 and remdesivir were tested

The agreement between Bristol Myers Squibb and Dragonfly Therapeutics includes DF6002, an extended half-life IL12 cytokine, which is being studied as a treatment for advanced solid tumours in

In October 2018, the companies first announced their collaboration for the discovery, development and commercialisation of advanced targeted immuno-oncology treatments for cancer. As part of the expanded multi-year

ASC22(Envafolimab) Phase IIa clinical trial is a single dose escalation study with three subcutaneously administered doses (0.3, 1.0 and 2.5 mg/kg) to explore the safety and efficacy of

Licensed from the Oxford University, the AZD1222 vaccine candidate had delivered strong immune responses against the Covid-19 causing SARS-CoV-2 virus in all participants in a phase I/II trial